President's address. Myasthenia gravis.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D001327:Autoimmune Diseases; D001763:Blepharoptosis / Q000150:complications; D004172:Diplopia / Q000150:complications; D004733:Enema / Q000009:adverse effects; D005260:Female; D049672:History, 19th Century; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D009388:Neostigmine / Q000627:therapeutic use; D011175:Positive-Pressure Respiration; D012737:Sex Factors; D013934:Thymectomy; D013945:Thymoma / Q000150:complications; D013953:Thymus Neoplasms / Q000150:complications; D013959:Thyroid Diseases / Q000150:complications
D009388:Neostigmine; D000324:Adrenocorticotropic Hormone